What are the recommended magnesium sulfate dosing regimens for its most common indications in adults (severe pre‑eclampsia/eclampsia, torsades de pointes, acute severe asthma, hypomagnesemia) and in children?

Magnesium Sulfate Dosing for Common Indications

For severe pre-eclampsia/eclampsia, use a 4-5 g IV loading dose over 5-20 minutes followed by 1-2 g/hour continuous infusion (or 4-5 g IM every 4 hours), targeting serum levels of 4.8-6 mg/dL; for torsades de pointes, administer 1-2 g IV push; for severe hypomagnesemia, give 1-2 g IV over 5-60 minutes or up to 5 g infused over 3 hours; and for acute severe asthma in children, use 25-75 mg/kg IV (maximum 2 g) over 20 minutes. 1

Pre-eclampsia and Eclampsia

Adult Dosing

The FDA-approved regimen for severe pre-eclampsia/eclampsia involves a total initial dose of 10-14 g 1:

Loading dose options:

• IV route: 4-5 g diluted in 250 mL D5W or normal saline, infused over 5-20 minutes
• Combined IV/IM: 4 g IV plus 10 g IM (5 g in each buttock simultaneously)

Maintenance dosing:

• IV continuous infusion: 1-2 g/hour (preferred in most settings)
• IM injections: 4-5 g IM into alternate buttocks every 4 hours as needed

Critical monitoring parameters:

• Target serum magnesium: 4.8-6 mg/dL (optimal for seizure control per FDA label) 1
• Maximum daily dose: 30-40 g/24 hours
• In severe renal insufficiency: maximum 20 g/48 hours with frequent serum level monitoring
• Do not exceed 5-7 days of continuous use in pregnancy (risk of fetal abnormalities) 1

Special Populations: Obese Women

Standard dosing frequently results in subtherapeutic levels in obese women (BMI ≥35). A 2020 randomized trial demonstrated that 100% of obese women receiving standard Zuspan dosing had subtherapeutic levels at 4 hours versus only 63% with higher dosing 2. Consider:

• Loading dose: 6 g IV over 15-20 minutes
• Maintenance: 2 g/hour continuous infusion

This alternate regimen more reliably achieves therapeutic concentrations (≥4.8 mg/dL) in obese patients 2.

Duration Considerations

Recent evidence suggests 12-hour regimens may be as effective as 24-hour regimens for seizure prevention with no difference in toxicity, though 24-hour protocols remain standard in most guidelines 3. The decision should be guided by clinical severity and institutional protocols.

Torsades de Pointes and Acquired Long QT

For recurrent torsades de pointes with acquired QT prolongation, IV magnesium sulfate is recommended regardless of baseline magnesium levels 4.

Dosing:

• 1-2 g IV push over 1-2 minutes for acute torsades
• May repeat as needed for recurrent episodes
• Simultaneously correct potassium to ≥4.0 mmol/L and magnesium to ≥2.0 mmol/L 4

If torsades persists despite IV magnesium, increase heart rate with temporary pacing or isoproterenol infusion 4. The guideline emphasizes that magnesium works even when serum magnesium is normal, likely through direct membrane effects rather than simple repletion.

Hypomagnesemia

Mild Deficiency

• 1 g IM every 6 hours × 4 doses (total 4 g over 24 hours)
• Equivalent to 8.12 mEq per dose, 32.5 mEq total 1

Severe Hypomagnesemia

Two options:

• High-dose IM: Up to 250 mg/kg (approximately 2 mEq/kg) within 4 hours if necessary
• IV infusion: 5 g (40 mEq) in 1 liter D5W or normal saline over 3 hours 1

Critical caveat: Monitor renal function closely—do not exceed renal excretory capacity. Reduce dosing in renal insufficiency.

Total Parenteral Nutrition (TPN)

• Adults: 8-24 mEq (1-3 g) daily
• Infants: 2-10 mEq (0.25-1.25 g) daily 1

Acute Severe Asthma

Pediatric Dosing

The 2009 NAEPP guidelines recommend considering IV magnesium sulfate for life-threatening exacerbations or those remaining severe after 1 hour of intensive conventional treatment 5.

Dosing:

• 25-75 mg/kg IV (maximum 2-2.5 g per dose)
• Infuse over 20 minutes
• Target peak plasma concentration >4 mg/dL as surrogate for efficacy 6

Important limitation: Magnesium has no apparent value in mild-to-moderate exacerbations—reserve for severe cases only 5. The evidence supports selective use in academic emergency departments for children who fail initial bronchodilator therapy.

Adult Dosing

While not extensively detailed in the provided asthma guidelines, the FDA label suggests 3-4 g IV over 30 seconds for severe bronchospasm, though this should be used with extreme caution 1.

Administration and Safety Considerations

Rate of Administration

• Standard IV push: Do not exceed 150 mg/minute (1.5 mL of 10% solution/minute)
• Exception: Severe eclampsia with active seizures may require faster administration 1

Dilution Requirements

• IV infusions: Dilute to ≤20% concentration before administration
• IM injections in children: Dilute 50% solution to ≤20% concentration
• IM injections in adults: May use undiluted 50% solution 1

Toxicity Monitoring

Clinical signs of toxicity (in ascending order of severity):

• Loss of patellar reflexes: 3.5-5 mmol/L (7-10 mg/dL)
• Respiratory depression: 5-6.5 mmol/L (10-13 mg/dL)
• Altered cardiac conduction: >7.5 mmol/L (>15 mg/dL)
• Cardiac arrest: >12.5 mmol/L (>25 mg/dL) 7

Essential monitoring:

• Deep tendon reflexes (patellar) before each dose
• Respiratory rate (must be >12-16/minute)
• Urine output (must be >25-30 mL/hour)
• Serum magnesium levels in renal insufficiency or prolonged therapy 7

Antidote: Keep calcium gluconate 1 g IV (10 mL of 10% solution) immediately available to reverse life-threatening toxicity 1.

Common Pitfalls

1. Failing to adjust for obesity: Standard dosing is inadequate in BMI ≥35—consider higher loading and maintenance doses 2
2. Continuing beyond 5-7 days in pregnancy: Risk of fetal skeletal abnormalities with prolonged use 1
3. Using in mild asthma: Reserve for severe/life-threatening exacerbations only 5
4. Inadequate renal monitoring: Magnesium is renally cleared—reduce doses and monitor levels closely in renal insufficiency 1
5. Drug interactions: Magnesium may reduce antibiotic activity of streptomycin, tetracycline, and tobramycin when co-administered 1